title: Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases.
abstract: It is unknown whether the high rates of cure reported for Burkitt lymphoma/leukemia (BL) patients treated with chemoimmunotherapy can be verified outside published series and clinical trials. We used the Surveillance Epidemiology and End Results (SEER) database to describe time trends in outcomes of BL in the United States. Cases were divided into 2 eras based on year of diagnosis, reflecting improvements in HIV management, BL treatment, and supportive care. There was a marked improvement in survival among BL cases diagnosed in the 2002-2008 era (n = 1922) relative to 1973-2001 (n = 1769) with 5-year relative survival estimates of 56% and 43%, respectively (P < .001). Five-year relative survival improved from 71% to 87% for ages 0 to 19 (n = 970), 35% to 60% for ages 20 to 39 (n = 897), 28% to 48% for ages 40 to 59 (n = 1047), and from 25% to 33% for ages ≥60 (n = 777). In multivariable analysis, the 2002-2008 era (HR = 0.76, P < .001) was associated with lower mortality. Conversely, older age, black race, and advanced stage were associated with higher mortality. More effective therapies are needed for older patients with BL, along with improved access to modern therapy for younger patients.
authors: Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425-6350, USA. costalj@musc.edu
authors: Luciano J
authors: LJ
authors: Costa
authors: Ana C
authors: AC
authors: Xavier
authors: Amy E
authors: AE
authors: Wahlquist
authors: Elizabeth G
authors: EG
authors: Hill
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002051:Burkitt Lymphoma / Q000401:mortality* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D016208:Databases, Factual; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D014481:United States / Q000453:epidemiology
references: Ann Oncol. 2012 Aug;23(8):2128-2137
references: 22241896
references: Cancer. 2007 Dec 1;110(11):2385-93
references: 17918260
references: Br J Haematol. 2008 Jun;141(6):840-7
references: 18371107
references: Cancer. 2003 Sep 15;98(6):1196-205
references: 12973843
references: JAMA. 2011 Apr 13;305(14):1450-9
references: 21486978
references: J Clin Oncol. 1996 Mar;14(3):925-34
references: 8622041
references: J Clin Oncol. 1999 Aug;17(8):2461-70
references: 10561310
references: Br J Haematol. 2012 Jan;156(2):234-44
references: 22098541
references: Ann Oncol. 2011 Aug;22(8):1859-64
references: 21339382
references: Blood. 2011 May 12;117(19):5019-32
references: 21300984
references: Cancer. 2006 Apr 1;106(7):1569-80
references: 16502413
references: Blood. 2010 Nov 18;116(20):e90-8
references: 20699439
references: Cancer. 2008 Jul 1;113(1):117-25
references: 18457327
references: Am J Hematol. 2012 Jan;87(1):22-5
references: 22086870
references: Blood. 2011 Aug 4;118(5):1248-54
references: 21653939
references: Blood. 2008 Sep 15;112(6):2248-60
references: 18612102
references: Blood. 2001 Jun 1;97(11):3370-9
references: 11369626
references: Blood. 2010 Dec 16;116(25):5600-4
references: 20813897
references: J Clin Oncol. 2000 Feb;18(4):813-23
references: 10673523
references: Adv Hematol. 2012;2012:735392
references: 22190945